Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.58 |
| ▸ | TDP2 | O95551 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31266449 | 0.85 | KMT2A (0.53) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL11910994 | 0.80 | KDM4E (0.52) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL13370787 | 0.80 | HSP90AA1 (0.53) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL31452767 | 0.77 | MMP14 (0.53) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL22281921 | 0.77 | CCR1 (0.50) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL25261222 | 0.77 | HSP90AA1 (0.53) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL30319517 | 0.77 | HSP90AA1 (0.53) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL21645154 | 0.77 | KDM4E (0.49) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL18980400 | 0.77 | L3MBTL1 (0.50) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL3381245 | 0.77 | KDM4E (0.49) | MEN1KMT2AAPAF1TDP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230183246-A1 | CONTINUOUS FLOW SONOGASHIRA COUPLING SYNTHESIS METHOD | PURDUE RESEARCH FOUNDATION (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183246-A1 | CONTINUOUS FLOW SONOGASHIRA COUPLING SYNTHESIS METHOD | PURDUE RESEARCH FOUNDATION (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183246-A1 | CONTINUOUS FLOW SONOGASHIRA COUPLING SYNTHESIS METHOD | PURDUE RESEARCH FOUNDATION (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4153568-A2 | CONTINUOUS FLOW SONOGASHIRA COUPLING SYNTHESIS METHOD | Purdue Research Foundation (US) | 2023-03-29 | — | — | EP | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| EP-4011882-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2018035072-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-1934216-B1 | NAPHTHYRIDIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-7511055-B2 | Naphthyridin derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1934216-A1 | NAPHTHYRIDIN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039512-A1 | NAPHTHYRIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078155-A1 | Naphthyridin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078155-A1 | Naphthyridin derivatives | GRM5, GRM3, GRM1 | MEN1 2575/4885KMT2A 2714/4885APAF1 4473/4885 |
| US-20230183246-A1 | CONTINUOUS FLOW SONOGASHIRA COUPLING SYNTHESIS METHOD | THPO, TALDO1, PAICS | MEN1 104/4885KMT2A 1097/4885APAF1 2873/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | MEN1 1979/4885KMT2A 927/4885APAF1 4685/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | MEN1 700/4885KMT2A 1206/4885APAF1 2657/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | MEN1 1930/4885KMT2A 593/4885APAF1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.